<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102348">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01694160</url>
  </required_header>
  <id_info>
    <org_study_id>2012/107 D</org_study_id>
    <secondary_id>2012-000429-32</secondary_id>
    <nct_id>NCT01694160</nct_id>
  </id_info>
  <brief_title>Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria</brief_title>
  <official_title>Consultant in Neprhology. MD. PhD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <authority>Norway: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to examine if paricalcitol may reduce progression of
      graft fibrosis and proteinuria in kidney transplant patients. Cyclosporine and tacrolimus
      have a detrimental long-term effect by inducing graft fibrosis. About 50% of graft losses
      are related to interstitial fibrosis. Paricalcitol is a vitamin D receptor activator
      indicated for treatment of secondary hyperparathyroidism. Paricalcitol is known to exert an
      anti-inflammatory and antifibrotic and attenuate cyclosporine-induced fibrosis. Paricalcitol
      is also shown to be renoprotective by reducing proteinuria. No randomized controlled trials
      with paricalcitol are performed in renal transplant patients examining the effect on
      proteinuria and graft fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Albumin exretion</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol 2 ug/daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  kidney transplant patients

        Exclusion Criteria:

          -  Previously transplanted
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hallvard Holdaas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital Rikshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renal Section, Oslo University Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hallvard Holdaas, MD, PhD</last_name>
      <phone>4723071247</phone>
      <email>hallvard.holdaas@oslo-universitetssykehus.no</email>
    </contact>
    <investigator>
      <last_name>Hallvard Holdaas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 26, 2012</lastchanged_date>
  <firstreceived_date>September 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Hallvard Holdaas</investigator_full_name>
    <investigator_title>Consultant Nephrology</investigator_title>
  </responsible_party>
  <keyword>kidney transplant patients</keyword>
  <keyword>Albuminuria</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
